ACADIA Pharmaceuticals (FRA:DR6) Total Liabilities : €360.1 Mil (As of Sep. 2024)

View and export this data going back to 2004. Start your Free Trial

What is ACADIA Pharmaceuticals Total Liabilities?

ACADIA Pharmaceuticals's Total Liabilities for the quarter that ended in Sep. 2024 was €360.1 Mil.

ACADIA Pharmaceuticals's quarterly Total Liabilities increased from Mar. 2024 (€359.77 Mil) to Jun. 2024 (€369.18 Mil) but then declined from Jun. 2024 (€369.18 Mil) to Sep. 2024 (€360.12 Mil).

ACADIA Pharmaceuticals's annual Total Liabilities increased from Dec. 2021 (€140.92 Mil) to Dec. 2022 (€176.91 Mil) and increased from Dec. 2022 (€176.91 Mil) to Dec. 2023 (€290.87 Mil).

ACADIA Pharmaceuticals Total Liabilities Historical Data

The historical data trend for ACADIA Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ACADIA Pharmaceuticals Total Liabilities Chart

ACADIA Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

75.64

127.91

140.92

176.91

290.87

ACADIA Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial															253.33	290.87	359.77	369.18	360.12

ACADIA Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

ACADIA Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	233.151	+	(43.833	+	13.889
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	290.9

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	686.793	-	395.919
	=	290.9

ACADIA Pharmaceuticals's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	309.894	+	(36.419	+	13.806
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	360.1

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	880.158	-	520.039
	=	360.1

ACADIA Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of ACADIA Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

ACADIA Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ACADIA Pharmaceuticals Inc (FRA:DR6) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

ACAD:USA 0A4W:UK

Address

12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130

Website

https://www.acadia.com

Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

ACADIA Pharmaceuticals Headlines

No Headlines